ClinicalTrials.gg
RecruitingNCT07594704Updated May 22, 2026

Effects of Different Tunnel Methods in PICC Catheterization

An interventional study of One-needle tunnel technique and two-needle tunnel technique in PICC Line Placement and PICC-associated Thrombosis, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Thrombosis with a site in China — 18 open to participants now, 20 under way, none of them phase 3. Thrombosis · China.

Planned enrollment
20th of 41
284 · median 274
Started
2026
with 3 others
No phase
15 of 67
2 open now
Primary completion
2026-06
later than 6 of 19 live
Registered
62nd of 67
by date
Lead sponsor
2 of 67
Sun Yat-sen University

Among the 67 studies in Thrombosis with a site in China, this one is the 20th largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2026, is one of 15 with no phase, reaches primary completion later than 6 of the 19 other live ones, and was the 62nd registered.

Thrombosis

956 studies on the registry are indexed under Thrombosis; 172 are open to participants now.

Browse Thrombosis studies →

Open to participants now

18 of the 67 studies in Thrombosis with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 128 Thrombosis studies recruiting now, 80 (63%) set no upper age limit and 17 (13%) stop at 75 or younger; 21 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Thrombosis with a site in China, or all of them as a file.
02

Study summary

This prospective randomized controlled trial compares the effectiveness and safety of one-needle and two-needle tunneling techniques for peripherally inserted central catheter (PICC) placement, aiming to identify the optimal tunneling method to reduce catheter-related complications.

03

Conditions studied

  • PICC Line Placement
  • PICC-associated Thrombosis

Keywords

  • tunnel
  • PICC
  • complications
  • thrombosis
  • infection
  • bleeding
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75 years old;
  • Educational level of primary school or above, with basic listening, speaking, reading and writing abilities, and capable of completing the questionnaire independently;
  • Receiving tunneled PICC catheterization for the first time, with 4Fr single-lumen solo PICC catheter indwelling;
  • Able to attend regular PICC maintenance at our hospital as scheduled after catheterization;
  • Voluntarily participate in this study and sign the form for this study as well as the informed consent form for PICC catheterization.

Exclusion criteria

Exclusion Criteria:

  • Patients with coagulation dysfunction ( > 1.5 / \< 50×10⁹/L);
  • Pregnant or lactating women;
  • Patients with \< 18.5 kg/m²;
  • Patients receiving PICC catheterization via lower extremity veins;
  • Patients with known or suspected allergy to components of PICC catheters.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
284 participants (estimated)

Study arms

  • Active comparator
    cancer patients who undergo PICC placement using two-needle tunnel technique

    Two-needle tunnel PICC procedure: 1. Local anesthesia at puncture and catheter exit sites; 2. Ultrasound-guided vascular puncture at puncture site, guide wire inserted via puncture needle; 3. Skin dilation at both puncture and exit sites; 4. 4cm saline tunnel created with 0.9% NaCl: 10mL syringe advanced along tunnel path while injecting solution; 5. Subcutaneous tunnel formed from exit site to puncture site with tunneling tool, catheter pulled through tunnel to puncture site; 6. Vascular sheath inserted over guide wire, catheter trimmed to length, advanced through sheath after guide wire removal; 7. Vascular sheath peeled off, catheter adjusted to proper position; 8. Catheter tip position confirmed; 9. Puncture site closed with suture-free tape, both sites covered with sterile dressings, catheter secured.

    Other: two-needle tunnel technique

  • Experimental
    cancer patients who undergo PICC placement using one-needle tunnel technique

    Ultrasound guidance is used for vascular puncture and assisted subcutaneous tunnel creation: 1. Local anesthesia is administered at the puncture site,the puncture needle travels 4 cm through the subcutaneous tissue before entering the blood vessel; 2. The guide wire is inserted along the puncture needle; 3. skin dilation; 4. The vascular sheath is advanced into the blood vessel via the guide wire, and the catheter is inserted through the vascular sheath; 5. The catheter tip position is confirmed, and the catheter is secured.

    Other: One-needle tunnel technique

Interventions

  • OtherOne-needle tunnel technique

    1. Local anesthesia is administered at the puncture site,Ultrasound guidance is used for vascular puncture and assisted subcutaneous tunnel creation,the puncture needle travels 4 cm through the subcutaneous tissue before entering the blood vessel; 2. The guide wire is inserted along the puncture needle; 3. skin dilation; 4. The vascular sheath is advanced into the blood vessel via the guide wire, and the catheter is inserted through the vascular sheath; 5. The catheter tip position is confirmed, and the catheter is secured.

  • Othertwo-needle tunnel technique

    Two-needle tunnel PICC procedure: 1. Local anesthesia at puncture and catheter exit sites; 2. Ultrasound-guided vascular puncture at puncture site, guide wire inserted via puncture needle; 3. Skin dilation at both puncture and exit sites; 4. 4cm saline tunnel created with 0.9% NaCl: 10mL syringe advanced along tunnel path while injecting solution; 5. Subcutaneous tunnel formed from exit site to puncture site with tunneling tool, catheter pulled through tunnel to puncture site; 6. Vascular sheath inserted over guide wire, catheter trimmed to length, advanced through sheath after guide wire removal; 7. Vascular sheath peeled off, catheter adjusted to proper position; 8. Catheter tip position confirmed; 9. Puncture site closed with suture-free tape, both sites covered with sterile dressings, catheter secured.

06

What researchers measure

Primary outcomes

  1. overall PICC-related complications after catheter placement

    these complications include catheter exit site oozing, contact dermatitis, venous thrombosis, infection, catheter displacement or dislodgement, mechanical phlebitis, catheter occlusion, and catheter fracture or damage.

    Time frame: 4 weeks after PICC placement

Secondary outcomes

  1. first-puncture success rate of PICC catheterization

    Time frame: day 1 during PICC catheterization

  2. pain score

    Evaluated by Numerical Rating Scale , a self-report tool where individuals rate their pain intensity from 0 (no pain) to 10 (worst possible pain),with higher scores indicating more severe pain.

    Time frame: Day 1 during PICC placement

  3. Bleeding during PICC placement

    Time frame: Day 1 during PICC placement

  4. unplanned catheter removal rate of PICC

    Time frame: 4 weeks after PICC placement

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2026, 2 months after the start.

Of 109 non-industry interventional studies with no phase under Thrombosis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 2 months is below that.

Counting every sponsor, half of 116 studies reached it within 24 months; a quarter within 9 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 19, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jul 30, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07594704
Responsible party
Zeyin Hu (Specialist Nurse, Sun Yat-sen University) — Principal investigator
First posted
May 19, 2026
Start date
Apr 1, 2026
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
May 22, 2026

Study contacts

Zeyin Hu
Contact
huzy@sysucc.org.cn
15899954190

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion